| GeneLibs

题目:: Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
作者:: Turski(Michelle L),Vidwans(Smruti J),Janku(Filip),Garrido-Laguna(Ignacio),Munoz(Javier),Schwab(Richard),Subbiah(Vivek),Rodon(Jordi),Kurzrock(Razelle)
状态:: 发布时间2016-05-20 , 更新时间 2016-05-20
期刊:: Mol Cancer Ther
摘要:: The diagnosis, classification, and management of cancer are traditionally dictated by the site of tumor origin, for example, breast or lung, and by specific histologic subtypes of site-of-origin cancers (e.g., non-small cell versus small cell lung cancer). However, with the advent of sequencing technologies allowing for rapid, low cost, and accurate sequencing of clinical samples, new observations suggest an expanded or different approach to the diagnosis and treatment of cancer-one driven by the unique molecular features of the tumor. We discuss a genomically driven strategy for cancer treatment using BRAF as an example. Several key points are highlighted: (i) molecular aberrations can be shared across cancers; (ii) approximately 15% of all cancers harbor BRAF mutations; and (iii) BRAF inhibitors, while approved only for melanoma, have reported activity across numerous cancers and related disease types bearing BRAF aberrations. However, BRAF-mutated colorectal cancer has shown poor response rate to BRAF inhibitor monotherapy, striking a cautionary note. Yet, even in this case, emerging data suggest BRAF-mutated colorectal cancers can respond well to BRAF inhibitors, albeit when administered in combination with other agents that impact resistance pathways. Taken together, these data suggest that molecular aberrations may be the basis for a new nosology for cancer. Mol Cancer Ther; 15(4); 533-47. ©2016 AACR.
语言:: eng
DOI:: 10.1158/1535-7163.MCT-15-0643

文献库文献相关信息

DataTable pData

联系方式

微信公众号

文献库 文献相关信息

DataTable pData

联系方式

微信公众号

文献库文献相关信息